title: Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.
abstract: Picornaviruses have emerged as promising cancer therapies due to their ability to drive cytotoxic cellular immune responses and for promoting oncolysis. These properties include preferential replication in tumor cells, the induction of strong innate and adaptive immune responses, and the ease with which their genomes can be manipulated. We have developed Theiler's murine encephalomyelitis virus (TMEV) as an immunotherapy vector that promotes strong adaptive immune responses to tumor antigens embedded within its genome. To further explore its usefulness as cancer therapy, we investigated whether direct intratumoral delivery of TMEV could promote tumor regression. We generated several picornavirus hybrids using substrains of TMEV that have unique immunopathologic characteristics, despite their extensive sequence homology. These hybrids exhibit a unique propensity to infect and replicate in melanoma. We have identified GD7-KS1, a virus that is particularly effective at replicating and infecting B16 melanoma in vitro and provides benefit as an oncolytic therapy in vivo after intratumoral injection. In addition, this virus promotes the mobilization and accumulation of CD8(+) T cells within treated tumors. Altogether, these findings demonstrate that picornavirus substrains can be used to rationally design virus hybrids that promote antitumor responses and add to the known strategies identified by us and others to further enhance the therapeutic potential of vectors used to treat cancer.
authors.affiliation: Department of Immunology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Bell
authors.affiliation: Department of Immunology, Mayo Clinic, Rochester, Minnesota. pavelko.kevin@mayo.edu.
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Pavelko
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D016923:Cell Death; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004195:Disease Models, Animal; D005260:Female; D005818:Genetic Engineering; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D006801:Humans; D015552:Injections, Intralesional; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000378:metabolism; D015412:Mastectomy, Segmental; D008546:Melanoma, Experimental; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D050130:Oncolytic Virotherapy; D010641:Phenotype; D010849:Picornaviridae / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay; D023041:Xenograft Model Antitumor Assays
chemical_list: D000951:Antigens, Neoplasm
references.citation: Cancer Res. 2002 Jul 1;62(13):3812-8
references.pmid: 12097294
references.citation: J Virol. 2000 May;74(9):4047-56
references.pmid: 10756016
references.citation: J Virol. 2002 Aug;76(16):8138-47
references.pmid: 12134019
references.citation: J Virol. 2002 Aug;76(16):8400-7
references.pmid: 12134043
references.citation: J Virol. 2003 Feb;77(4):2709-16
references.pmid: 12552011
references.citation: Eur J Immunol. 2003 Sep;33(9):2501-10
references.pmid: 12938226
references.citation: Cancer Res. 2004 Jul 15;64(14):4919-26
references.pmid: 15256464
references.citation: Proc Natl Acad Sci U S A. 1990 Jun;87(11):4125-9
references.pmid: 2161533
references.citation: J Virol. 1992 Jul;66(7):4508-17
references.pmid: 1602556
references.citation: J Virol. 1996 May;70(5):2861-8
references.pmid: 8627760
references.citation: Virology. 1996 Jun 1;220(1):246-50
references.pmid: 8659122
references.citation: J Neurovirol. 1996 Apr;2(2):70-7
references.pmid: 8799198
references.citation: Virology. 1996 Dec 1;226(1):135-9
references.pmid: 8941332
references.citation: Virology. 1998 May 10;244(2):397-404
references.pmid: 9601508
references.citation: Arch Virol. 1997;142(8):1521-35
references.pmid: 9672616
references.citation: J Virol. 1998 Sep;72(9):7213-20
references.pmid: 9696815
references.citation: J Virol. 1999 Feb;73(2):958-64
references.pmid: 9882296
references.citation: J Virol. 1999 May;73(5):3702-8
references.pmid: 10196262
references.citation: Exp Hematol. 2006 Jun;34(6):713-20
references.pmid: 16728275
references.citation: Microb Pathog. 2006 Oct-Nov;41(4-5):149-56
references.pmid: 16935465
references.citation: Cancer Res. 2007 Mar 15;67(6):2840-8
references.pmid: 17363607
references.citation: J Exp Med. 2007 Oct 29;204(11):2667-77
references.pmid: 17954566
references.citation: Cell Host Microbe. 2008 Sep 11;4(3):239-48
references.pmid: 18779050
references.citation: Nat Med. 2008 Nov;14(11):1278-83
references.pmid: 18953352
references.citation: Nature. 2009 Jun 18;459(7249):1005-9
references.pmid: 19421193
references.citation: Cancer Res. 2010 Jun 1;70(11):4539-49
references.pmid: 20484025
references.citation: PLoS One. 2011;6(5):e20217
references.pmid: 21625449
references.citation: J Virol. 2012 Mar;86(5):2750-9
references.pmid: 22171271
references.citation: Nat Methods. 2012 Jul;9(7):671-5
references.pmid: 22930834
references.citation: BMC Microbiol. 2012;12:162
references.pmid: 22853823
references.citation: Mol Ther. 2013 May;21(5):1087-95
references.pmid: 23568262
references.citation: Mol Cancer Ther. 2013 Oct;12(10):1935-46
references.pmid: 23974695
references.citation: N Engl J Med. 2014 Apr 24;370(17):1615-25
references.pmid: 24716661
references.citation: Mayo Clin Proc. 2014 Jul;89(7):926-33
references.pmid: 24835528
references.citation: Nat Rev Cancer. 2014 Aug;14(8):559-67
references.pmid: 24990523
references.citation: Cancer. 2014 Nov 1;120(21):3277-86
references.pmid: 24939611
references.citation: Adv Cancer Res. 2015;126:305-44
references.pmid: 25727152
references.citation: Mol Cancer. 2015;14:15
references.pmid: 25623282
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6803-8
references.pmid: 10841575
references.citation: Virology. 2000 Sep 15;275(1):77-88
references.pmid: 11017789
references.citation: Cancer Res. 2001 Feb 1;61(3):813-7
references.pmid: 11221860
references.citation: Molecules. 2015;20(5):7509-27
references.pmid: 25919275
references.citation: PLoS One. 2015;10(5):e0125565
references.pmid: 25933216
references.citation: Virus Res. 2015 Aug 3;206:62-73
references.pmid: 25617758
references.citation: J Virol. 2000 Feb;74(4):1994-2004
references.pmid: 10644372
references.citation: J Biol Chem. 2002 Jul 12;277(28):25697-702
references.pmid: 11983699